Frequency distribution of CMV genotypes gB 1 through 4
| . | Total CMV+patients . | gB type 1 . | gB type 2 . | gB type 3 . | gB type 4 . | Total strains detected* . |
|---|---|---|---|---|---|---|
| AA patient marrow (n = 100) | 33 | 8 (21%) | 9 (23%) | 19 (50%) | 2 (5%) | 38 |
| Control patient marrow (n = 151) | 19 | 8 (40%) | 6 (30%) | 5 (25%) | 1 (5%) | 20 |
| Clinical isolates all sites (n = 281)† | 281 | 137 (46%) | 49 (18%) | 76 (26%) | 26 (9%) | 288 |
| . | Total CMV+patients . | gB type 1 . | gB type 2 . | gB type 3 . | gB type 4 . | Total strains detected* . |
|---|---|---|---|---|---|---|
| AA patient marrow (n = 100) | 33 | 8 (21%) | 9 (23%) | 19 (50%) | 2 (5%) | 38 |
| Control patient marrow (n = 151) | 19 | 8 (40%) | 6 (30%) | 5 (25%) | 1 (5%) | 20 |
| Clinical isolates all sites (n = 281)† | 281 | 137 (46%) | 49 (18%) | 76 (26%) | 26 (9%) | 288 |
Among the 33 CMV+ AA patients, 4 had a gB 2/3 mix, 1 had a gB 3/4 mix. Among the 19 CMV+ control patients, 1 had a gB 2/3 mix. Among the 281 clinical isolates cultured from CMV+ patients, 3 had a gB 2/3 mix, 3 had a gB 3/4 mix, and 1 had a gB 1/3 mix.
Previously reported.5 gB frequency among viral isolates cultured from infected patients.